AzTrials
AzTrials

UTI - Urinary Tract InfectionNCT07189429

Clinical Impact Analysis of PA-100 AST in a Spanish GP Setting

A study testing PA-100 AST in people with UTI - Urinary Tract Infection and UTI - Lower Urinary Tract Infection, run by Sysmex Europe GmbH at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Assessment of workflow implications of the PA-100 AST System. Using well-defined data collection protocols, the study comprises the following: Collection of clean-catch midstream urine samples Measurement of specimens on the PA-100 AST System o Antibiotics tested: Amoxicillin/clavulanic acid (AMC), Ciprofloxacin… Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
PA-100 AST
Could I receive a placebo?
No, everyone receives an active treatment
How many people
199 participants
Where
1 siteSpain
Study dates
1 Jul 2024to 30 Aug 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients were recruited according to the following criteria: non-pregnant female, >18 years old, presenting with acute UTI symptoms that had been present for < 7 days (symptoms according to the current guidelines [EAU]), with no antibiotic treatment within the previous 7 days, positive urine dipstick for leukocyte esterase (LEU) and/or nitrites (NIT) and who provided a clean-catch mid-stream urine sample.

Who cannot join

  • Withdraw of consent

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Centro de Salud Ensanche de Vallecas

    Madrid

Other trials in Spain

About this study

Official title: PA-100 Workflow Assessment

Assessment of workflow implications of the PA-100 AST System.

Using well-defined data collection protocols, the study comprises the following:

  • Collection of clean-catch midstream urine samples
  • Measurement of specimens on the PA-100 AST System
  • Antibiotics tested: Amoxicillin/clavulanic acid (AMC), Ciprofloxacin (CIP), Trimethoprim (TRI), Fosfomycin (FOS) and Nitrofurantoin (NIT)
  • Treatment of patients according to the results of the tests on the PA-100 AST System
  • Collection of data about patient treatment and antibiotic prescription when the PA-100 AST System is not used (study baseline)
  • Collection of patient related information
  • Collection of workflow-related information, including doctors and nurses at the test location
  • Evaluation of changes in the prescription behaviour when using the PA-100 AST System, compared to current practice at the Test Location
Read the detailed description

Uncomplicated cystitis in females is among the most frequent community-acquired infections. Urinary tract infection (UTI) is classified as uncomplicated if it occurs in patients with a structurally and functionally normal urinary tract in otherwise healthy, non-pregnant women. Such acute uncomplicated UTIs occur frequently and are associated with high morbidity. Approximately one third of women up to 24 years of age have experienced uncomplicated UTI.

The current gold standard for UTI diagnosis is urine culture of a midstream, clean-catch urine specimen, followed by antibiotic susceptibility testing (AST). UTI patients are often treated empirically with antibiotics, and most guidelines recommend starting antibiotic treatment without or before urine culture and AST results become available. This results in patient treatment without laboratory evidence or at least in a delay of targeted antibacterial therapy by approximately 48 h, when applicable. Due to the continually changing local rates of antimicrobial resistance, empiric treatments do not ensure appropriate stewardship and can result in therapeutic failure.

Therefore, rapid and accurate diagnosis, leading to evidence-based treatment, is essential to achieve a timely and effective therapy.

With antibiotic resistance rates for common antibiotics reaching values as high as 20% of bacteria, the current empiric treatment at GP level carries the risk of clinical failure and the possibility to further increase the prevalence of antibiotic resistant strains.

A point-of-care test (POCT) is defined as a diagnostic tool applicable near the site of patient care that has the potential to provide an accurate and fast diagnostic result. Several POCTs for UTI have been developed and are currently commercially available to detect the presence of bacteria or their activity in urine samples, including both culture-based and enzymatic assays, also in automated format. Existing POC tests, however, cannot provide rapid AST results during the patients first doctor visit, resulting in a delay of personalized treatment. It is the goal of the PA-100 AST System to perform a fast, automated and objective results for bacteriuria detection and AST results in less than 45 minutes and independent from the operator determination of bacteriuria and AST test.

The following investigation serves as a pilot study to better understand the potential and performance of the PA-100 Analyzer in combination with the PA-AST Panel U-0501. PA-100 AST System refers to PA-100 Analyzer in conjunction with the PA-AST Panel U-0501.

Being tested
PA-100 AST
Keywords
Clinical impact investigation, PA-100 AST
Medical subject headings
Urinary Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PA-100 ASTDiagnostic test

    Results of the PA-100 AST were made available to the treating physician

Study groups in NCT07189429
Study groupRoleWhat they receive
Standard of CareNo interventionPatients were managed according to local guidelines for uncomplicated community acquired urinary tract infection
Standard of Care with PA.100 ASTExperimentalPatients were managed according to local guidelines for uncomplicated community acquired urinary tract infection while having the additional information of PA-100 AST available during treatment decision.
Receives: Diagnostic Test: PA-100 AST

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Frequency of antibiotic prescription

    Measured: At initial GP visit

Secondary outcomes (1)
  1. Type of antibiotic prescribed

    Measured: At initial GP visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Sep 2025
  2. Study start1 Jul 2024
  3. Primary completion30 Jun 2025
  4. Study completion30 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
199 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07189429
Sponsor's protocol ID
SEU-MSD-PA100II
Status last verified
Sep 2025
First submitted
16 Sep 2025
Last updated
24 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Not included in ethical review assesment

Questions about this trial

What is this clinical trial studying?

A study testing PA-100 AST in people with UTI - Urinary Tract Infection and UTI - Lower Urinary Tract Infection, run by Sysmex Europe GmbH at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Frequency of antibiotic prescription (time frame: At initial GP visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in